Latest News - Valeant

Tuesday, March 28, 2017 | Corporate Lawsuits, Valeant

Former Valeant CEO Michael Pearson Sues Company Over Unpaid Share Award

Former Valeant Pharmaceuticals CEO Michael Pearson filed a lawsuit in the US claiming that the company failed to deliver 3 million shares promised to him as part of an exit package. According to the c…

Read the full story

Tuesday, March 14, 2017 | Earnings & Financials, Valeant

Ackman Unloads Entire Stake in Valeant

After a long relationship that has seen the rapid rise and massive fall of Valeant’s stock price, Pershing Square Capital Management CEO Bill Ackman stated that his hedge fund has sold all its s…

Read the full story

Tuesday, February 21, 2017 | Acquisitions/Mergers, Eyegate Pharmaceuticals, Valeant

Valeant and Eyegate Enter into Licensing Agreement for EyeGate II Delivery System and EGP-437 Combination Product

Valeant Pharmaceuticals International and EyeGate Pharmaceuticals announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Va…

Read the full story

Thursday, December 01, 2016 | Acquisitions/Mergers, Valeant

Valeant Drops After Report Salix Sale Discussions Broke Down

Valeant Pharmaceuticals International Inc. dropped after a report that discussions to sell its gastrointestinal drugs unit to Japan’s Takeda Pharmaceutical Co. for about $10 billion have fallen …

Read the full story

Thursday, November 17, 2016 | Miscellaneous, Valeant

Ex-Valeant Executive, Ex-Pharmacy CEO Charged for Fraud Scheme

US prosecutors on Thursday filed charges against a former Valeant Pharmaceuticals International executive and a former CEO of mail order pharmacy Philidor Rx Services, alleging they engaged in a multi…

Read the full story

Wednesday, November 09, 2016 | Miscellaneous, Bausch+Lomb, Nicox , Valeant

Nicox Provides Update on Latanoprostene Bunod and AC-170

Nicox SA provided an update on the regulatory status of its key projects, latanoprostene bunod and AC-170. Valeant Pharmaceuticals has stated that Nicox's licensee for latanoprostene bunod, Bau…

Read the full story

Tuesday, November 08, 2016 | Earnings & Financials, Valeant

Valeant Shares Plunge as It Slashes Guidance Again

Valeant Pharmaceuticals International Inc. cut its annual outlook again Tuesday as the drug company, struggling to remake its business after a series of missteps, signaled its turnaround may take long…

Read the full story

Tuesday, November 08, 2016 | Acquisitions/Mergers, Earnings & Financials, Bausch+Lomb, Paragon BioTeck, Valeant

Valeant Agrees to Sell Paragon to Settle U.S. Antitrust Charges

Valeant Pharmaceuticals, which owns eye care products maker Bausch & Lomb, has agreed to sell Paragon Holdings to settle allegations that its acquisition of the smaller company was illegal under a…

Read the full story

Thursday, November 03, 2016 | Acquisitions/Mergers, Bausch+Lomb, Valeant

Valeant Exploring Sale of Eye Surgery Equipment Business

New reports reveal that Valeant is exploring a sale of its eye surgery equipment business – part of its Bausch + Lomb franchise – in an effort to pay down debt. The Wall Street Journal, citing …

Read the full story

Tuesday, November 01, 2016 | Earnings & Financials, Valeant

Valeant Said to Be in Talks for Sale of Salix to Takeda

Valeant Pharmaceuticals International is in talks to sell its Salix gastrointestinal drugs business to Takeda Pharmaceutical Co., according to a person familiar with the matter. The unit could go for …

Read the full story

Monday, October 31, 2016 | Earnings & Financials, Valeant

Valeant Ex-CEO, Ex-CFO Are Focus of U.S. Criminal Probe

U.S. prosecutors are focusing on Valeant Pharmaceuticals International Inc.’s former CEO and CFO as they build a fraud case against the company that could yield charges within weeks, according t…

Read the full story

Friday, September 23, 2016 | Health Care, Valeant

Valeant Avoids Double-Digit Price Hikes With 9.9 Percent Increases

In response to intensifying criticism over drug prices, Allergan chief executive Brent Saunders promised not to raise prices by more than single-digit percentage points. So far, no other head of a lar…

Read the full story

Monday, August 22, 2016 | Management/Leadership, Valeant

Valeant Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer

Valeant Pharmaceuticals International announced that Paul S. Herendeen has been appointed Executive Vice President, Finance and will take over the role of Chief Financial Officer from Robert L. Rosiel…

Read the full story

Thursday, August 18, 2016 | Earnings & Financials, Valeant

Valeant Shares Rise as Once-Burned Analysts Regain Optimism

Stock analysts are starting to come back around to Valeant Pharmaceuticals International Inc. after being burned by the company over the past year. The shares rose 13 percent to $30 at 4 p.m. Wednesda…

Read the full story

Wednesday, August 10, 2016 | Earnings & Financials, Valeant

Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results

  Total Revenues of $2.4 billion, a decrease of 11% versus the second quarter of 2015 GAAP EPS  ($0.88) and Adjusted EPS (non-GAAP)  $1.40 Cash Flow from Operations of $448 …

Read the full story
Load More